← Back to Clinical Trials
Recruiting NCT06471127

Neuroplasticity Biomarkers in Aphasia

Trial Parameters

Condition Aphasia
Sponsor University of Wisconsin, Madison
Study Type INTERVENTIONAL
Phase N/A
Enrollment 90
Sex ALL
Min Age 40 Years
Max Age 90 Years
Start Date 2025-03-17
Completion 2029-05-31
Interventions
Pseudoword learning paradigm task

Brief Summary

Patients with stroke frequently suffer from aphasia, a disorder of expressive and/or receptive language, that can lead to serious health consequences, including social isolation, depression, reduced quality of life, and increased caregiver burden. Aphasia recovery varies greatly between individuals, and likely relies upon the capacity for neuroplasticity, both at a systems level of reorganized brain networks and a molecular level of neuronal repair and plasticity. The proposed work will evaluate genetic and neural network biological markers of neuroplasticity associated with variability in aphasia, with a future goal to improve prognostics and identify therapeutic targets to reduce the long-term burdens of aphasia.

Eligibility Criteria

Inclusion Criteria: 1. Ages 40-90 2. Right-handed (prior to stroke) 3. Proficient English speakers 4. History of a single ischemic stroke in the middle cerebral artery territory that is lateralized to the left or right (Aim 1) cerebral hemisphere. 5. Presence of aphasia (Aims 2-3) 6. Capacity to understand the nature of the study and provide informed consent 7. Acute or subacute stroke at the time of Aim 1 enrollment; Stroke #12 months old (chronic) at the time of Aims 2-3 enrollment 8. Medically stable Exclusion Criteria: 1. History of significant medical or neurological disorder (other than stroke) 2. History of significant or poorly controlled psychiatric disorders 3. Current abuse of alcohol or drugs, prescription or otherwise 4. Clinically significant and uncorrected vision or hearing loss 5. Anything other than standard of care stroke treatment such as Plavix, aspirin (81-300 mg daily), beta-blockers, diabetes medications or choles- terol-lowering agents, thrombolytics (e.g., tPA

Related Trials